Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Link opens in a new tab
Search content at Tel Aviv University
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Vaccination for SARS-CoV-2 in Hematological Patients
Niccolò Riccardi
, Marco Falcone
,
Dafna Yahav
*
*
Corresponding author for this work
Internal Medicine
Azienda Ospedaliero Universitaria Pisana
Rabin Medical Center Israel
Research output
:
Contribution to journal
›
Review article
›
peer-review
19
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Vaccination for SARS-CoV-2 in Hematological Patients'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Vaccination
100%
Oncology Patients
100%
COVID-19
100%
Hematological Malignancies
75%
Coronavirus Disease 2019 Vaccine
75%
Patients with Hematological Malignancies
50%
Humoral Response
50%
Immune Response
25%
Disease Prevention
25%
Response Rate
25%
Highly Effective
25%
Severe Disease
25%
Randomized Controlled Trial
25%
High Response Rate
25%
Chronic Myeloid Leukemia
25%
Adverse Events
25%
Immunocompromised Patients
25%
Multiple Myeloma Patients
25%
Lymphoproliferative Disorders
25%
Non-Hodgkin Lymphoma
25%
Chronic Lymphocytic Leukemia
25%
Serological Test
25%
Response to Vaccination
25%
Vaccine Effectiveness
25%
Antibody Level
25%
T Cell Response
25%
Leukemia Disease
25%
Seropositivity Rate
25%
Antibody Protection
25%
Low Immunogenicity
25%
Nonrandomized Studies
25%
Anti-CD20 Antibody
25%
Chimeric Antigen Receptor T-cell Therapy
25%
Myeloproliferative Neoplasms
25%
Full Vaccination
25%
Hematopoietic Stem Cell Transplant
25%
MRNA Vaccine
25%
Venetoclax
25%
Bruton Tyrosine Kinase Inhibitor
25%
Ruxolitinib
25%
Third mRNA Vaccine Dose
25%
Medicine and Dentistry
Hematologic Malignancy
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
COVID-19
60%
Infection
40%
Humoral Immunity
40%
Randomized Controlled Trial
20%
Chronic Myelogenous Leukemia
20%
Adverse Event
20%
Myeloproliferative Disorder
20%
Lymphoproliferative Disease
20%
B-Cell Chronic Lymphocytic Leukemia
20%
Multiple Myeloma
20%
Immune Response
20%
Immunogenicity
20%
Hematopoietic Stem Cell Transplantation
20%
T-Cell Response
20%
Chimeric Antigen Receptor T-Cell Immunotherapy
20%
Immunocompromised Patient
20%
Patient with Non-Hodgkins Lymphoma
20%
CD20 Antibody
20%
mRNA Vaccine
20%
Bruton Tyrosine Kinase Inhibitor
20%
Ruxolitinib
20%
Venetoclax
20%
Messenger RNA
20%
Diseases
20%